TNO155 is a Selective SHP2 Inhibitor to Target -dependent Oral Squamous Cell Carcinoma

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Nov 11

PMID 39524880

Authors

Annie Wai Yeeng Chai

Yee Hua Tan

Shiyin Ooi

Pei San Yee

Shi Mun Yee

Sok Ching Cheong

Affiliations

Soon will be listed here.

Abstract

Oral squamous cell carcinoma (OSCC) is known to be driven by multiple intricated receptor tyrosine kinases (RTKs) including EGFR, PI3K/AKT and MAPK signaling pathways. However, whilst targeting EGFR with cetuximab has been approved for the treatment of OSCC, other single-agent inhibitors of the RTKs have shown modest effects in improving survival. From the genome-wide CRISPR/Cas9 screen on 21 OSCC cell lines, we have identified among the top essential genes in OSCC. encodes for SHP2, a phosphatase that acts as a master signal transducer, downstream of various RTKs. Although overexpression has been reported in OSCC, little is known about its role as an essential gene for OSCC survival and its potential as a therapeutic target. Herein, we confirmed that is an essential gene in OSCC where its deletion significantly impacted cell survival. We evaluated three SHP2 inhibitors on 21 OSCC cell lines and found TNO155 to be significantly associated with CRISPR dependency score. We showed that TNO155 caused dose-dependent suppression on p-ERK and p-MEK, and suppresses the JAK/STAT pathway via downregulating p-JAK1, p-STAT1, p-STAT3. Furthermore, we confirmed that the combination of the mTOR inhibitor, everolimus with TNO155 is synergistic in OSCC. In summary, is a promising therapeutic target in OSCC that can be selectively targeted by SHP2 inhibitor such as TNO155. Our findings on the use of mTOR inhibitor, everolimus to overcome resistance to TNO155 are essential to inform on next phases of clinical trials which is warranted for the treatment of OSCC.

Citing Articles

Implication of protein post translational modifications in gastric cancer.

Song H, Zhang M, Guo C, Guo X, Ma Y, Ma Y Front Cell Dev Biol. 2025; 13:1523958.

PMID: 39968176 PMC: 11833226. DOI: 10.3389/fcell.2025.1523958.

References

Huang L, Fu L . Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015; 5(5):390-401. PMC: 4629442. DOI: 10.1016/j.apsb.2015.07.001. View

Nadhan R, Srinivas P, Pillai M . RTKs in pathobiology of head and neck cancers. Adv Cancer Res. 2020; 147:319-373. DOI: 10.1016/bs.acr.2020.04.008. View

Ngan H, Law C, Choi Y, Chan J, Lui V . Precision drugging of the MAPK pathway in head and neck cancer. NPJ Genom Med. 2022; 7(1):20. PMC: 8927572. DOI: 10.1038/s41525-022-00293-1. View

Nathan C, Hayes D, Karrison T, Harismendy O, Flores J, Moore-Medlin T . A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck. Clin Cancer Res. 2022; 28(23):5040-5048. PMC: 9722644. DOI: 10.1158/1078-0432.CCR-21-4290. View

LaMarche M, Acker M, Argintaru A, Bauer D, Boisclair J, Chan H . Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. J Med Chem. 2020; 63(22):13578-13594. DOI: 10.1021/acs.jmedchem.0c01170. View

Jiang M, Li B . STAT3 and Its Targeting Inhibitors in Oral Squamous Cell Carcinoma. Cells. 2022; 11(19). PMC: 9563058. DOI: 10.3390/cells11193131. View

Chou T . Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010; 70(2):440-6. DOI: 10.1158/0008-5472.CAN-09-1947. View

Prahallad A, Heynen G, Germano G, Willems S, Evers B, Vecchione L . PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell Rep. 2015; 12(12):1978-85. DOI: 10.1016/j.celrep.2015.08.037. View

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

10.

Zhang G, Wang Q, Qi X, Yang H, Su X, Yang M . OShnscc: a novel user-friendly online survival analysis tool for head and neck squamous cell carcinoma based on RNA expression profiles and long-term survival information. J Zhejiang Univ Sci B. 2022; 23(3):249-257. PMC: 8913923. DOI: 10.1631/jzus.B2100512. View

11.

Nichols R, Haderk F, Stahlhut C, Schulze C, Hemmati G, Wildes D . RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat Cell Biol. 2018; 20(9):1064-1073. PMC: 6115280. DOI: 10.1038/s41556-018-0169-1. View

12.

Grossmann K, Rosario M, Birchmeier C, Birchmeier W . The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res. 2010; 106:53-89. DOI: 10.1016/S0065-230X(10)06002-1. View

13.

Chai A, Lim K, Cheong S . Translational genomics and recent advances in oral squamous cell carcinoma. Semin Cancer Biol. 2019; 61:71-83. DOI: 10.1016/j.semcancer.2019.09.011. View

14.

Garcia Fortanet J, Chen C, Chen Y, Chen Z, Deng Z, Firestone B . Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. J Med Chem. 2016; 59(17):7773-82. DOI: 10.1021/acs.jmedchem.6b00680. View

15.

Mali S . Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer. Oral Oncol. 2015; 51(6):565-9. DOI: 10.1016/j.oraloncology.2015.03.004. View

16.

Kong J, Long Y . Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors. RSC Med Chem. 2022; 13(3):246-257. PMC: 8942255. DOI: 10.1039/d1md00386k. View

17.

Heynen G, Lisek K, Vogel R, Wulf-Goldenberg A, Alcaniz J, Montaudon E . Targeting SHP2 phosphatase in breast cancer overcomes RTK-mediated resistance to PI3K inhibitors. Breast Cancer Res. 2022; 24(1):23. PMC: 8974145. DOI: 10.1186/s13058-022-01521-3. View

18.

Reischmann N, Schmelas C, Molina-Vila M, Jordana-Ariza N, Kuntze D, Garcia-Roman S . Overcoming MET-mediated resistance in oncogene-driven NSCLC. iScience. 2023; 26(7):107006. PMC: 10391663. DOI: 10.1016/j.isci.2023.107006. View

19.

Chai A, Yee P, Price S, Yee S, Lee H, Tiong V . Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway. Elife. 2020; 9. PMC: 7591259. DOI: 10.7554/eLife.57761. View

20.

Bonner J, Harari P, Giralt J, Cohen R, Jones C, Sur R . Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2009; 11(1):21-8. DOI: 10.1016/S1470-2045(09)70311-0. View